Article Text

Download PDFPDF

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
  1. John Powderly1,
  2. Gregory Cote2,
  3. Keith Flaherty2,
  4. Russell Z Szmulewitz3,
  5. Antoni Ribas4,
  6. Jeffrey Weber5,
  7. Deryk Loo6,
  8. Jan Baughman6,
  9. Francine Chen6,
  10. Paul Moore7,
  11. Ezio Bonvini7,
  12. James Vasselli7,
  13. Jon Wigginton7,
  14. Roger Cohen8,
  15. Howard Burris9 and
  16. Bartosz Chmielowski10
  1. Aff1 grid.488747.0Carolina BioOncology Institute Huntersville NC USA
  2. Aff2 grid.32224.350000000403869924Department of OncologyMassachusetts General Hospital and Harvard Medical School Boston MA USA
  3. Aff3 grid.170205.10000000419367822University of Chicago Chicago IL USA
  4. Aff4 grid.413083.d0000000091428600University of California at Los Angeles Medical Center Los Angeles CA USA
  5. Aff5 grid.170693.a000000012353285XH. Lee Moffitt Cancer Center Tampa FL USA
  6. Aff6 grid.421076.60000 0004 0432 6278MacroGenics San Francisco CA USA
  7. Aff7 grid.421076.60000 0004 0432 6278MacroGenics Rockville MD USA
  8. Aff8 grid.25879.310000000419368972University of Pennsylvania Philadelphia PA USA
  9. Aff9 grid.419513.b0000000404595478Sarah Cannon Research Institute Nashville TN USA
  10. Aff10 grid.19006.3e0000000096326718Division of Hematology - Medical OncologyUCLA Jonsson Comprehensive Cancer Center Los Angeles CA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


MGA271 is a humanized IgG1 monoclonal antibody-targeting B7-H3 (CD276), a member of the B7 family. MGA271 has been Fc-engineered to enhance binding to activating FcγR (CD16A), decrease binding to inhibitory FcγR (CD32B), and potentiate ADCC. B7-H3 has limited expression in normal tissues but highly expressed in a broad range of tumors, making it an attractive target for cancer immunotherapy. We initiated a Phase I investigation of the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MGA271.


This Phase I study included dose escalation (complete) and an ongoing two-component cohort expansion (NCT01391143). Dose escalation utilized single-patient, intra-patient escalation, followed by a conventional 3+3 design, using MGA271 doses of 0.01-15mg/kg. MGA271 was administered weekly on a 4-week on, 4-week off schedule during cycle 1, and 3 out of every 4 weeks in subsequent cycles. Initial expansion cohorts enrolled patients (N=15/cohort) with melanoma, prostate carcinoma and other B7-H3+ tumors. Major modifications were subsequently made to enhance the functionality of the study prior to enrolling additional expansion cohorts. MGA271 administration was changed to uninterrupted weekly dosing, corticosteroid infusion reaction prophylaxis was reduced and immune-related response criteria and management principles were implemented. The additional expansion cohorts (N=16/cohort) were initiated in patients with melanoma (post checkpoint inhibitor), squamous cell head and neck carcinoma, renal cell carcinoma, triple-negative breast carcinoma, and high-B7-H3 expressing tumors including bladder and lung carcinoma. Pharmacodynamic testing included serum cytokines and modulation of the lymphocyte phenotype and T cell repertoire in peripheral blood.


MGA271 was well tolerated, with no dose-limiting toxicity and no maximum tolerated dose defined up to 15 mg/kg. Patients were frequently heavily pre-treated, with a median of 3 (0-7) prior therapies. Any grade treatment-related AEs occurred in 71% of patients, including fatigue (30%), infusion-related reaction (26%), nausea (19%), chills (17%) and vomiting (13%). Grade 3/4 drug related AEs were noted in 6% of patients. No drug-related AEs led to study drug discontinuation. MGA271 showed linear PK. As of 30 July 2015, 20 of 46 patients treated under the new study design continue on study drug. Patients experienced disease stabilization (>12 weeks) and tumor shrinkage (2-69%) across several tumor types. The study continues to enroll patients and generate more mature data.


MGA271 has a favorable safety profile and initial evidence of anti-tumor activity across several tumor types. These data support continued evaluation of MGA271 monotherapy and in combination with other immune modulators, including checkpoint inhibitors.

Trial Registration Identifier NCT01391143